New Treatments & Clinical Trials for Dilated Cardiomyopathy

Dilated cardiomyopathy means the heart's main pumping chamber enlarges and weakens, reducing its ability to pump blood. It's a leading cause of heart failure and heart transplant. Treatment combines medications to reduce strain on the heart, devices like pacemakers or defibrillators, and in severe cases transplant.

What's actually going on in research

Trials are testing gene therapies for inherited forms caused by mutations in TTN, LMNA, and other genes. Researchers are studying heart regeneration approaches using stem cells, drugs that strengthen heart muscle contraction, and new ways to reverse scarring. Device trials explore systems that support the failing heart without full transplant.

What to know before you search

Eligibility typically depends on ejection fraction, heart failure symptoms, genetic testing results, and whether you've had prior device placement or transplant.

What types of trials are currently open

• Gene therapy trials — Testing viral vectors that deliver corrected genes to heart muscle in people with inherited forms of dilated cardiomyopathy.
• Medication trials — Studies of new drugs that strengthen heart contraction, reduce scarring, or protect heart muscle cells from further damage.
• Device trials — Testing ventricular assist devices, pacemaker systems, and other implanted tools that support or regulate heart function.
• Cell therapy trials — Injecting stem cells or modified heart cells to see if they can repair damaged heart muscle and improve pumping.
• Transplant studies — Research on organ preservation, rejection prevention, and expanding the donor pool for people who need heart transplant.